Canaccord Genuity Reiterates Hold on Genomic Health (GHDX)

By admin | 7 years ago

Genomic Health (NASDAQ: GHDX)‘s stock had its “hold” rating restated by equities researchers at Canaccord Genuity in a report issued on Thursday.

Shares of Genomic Health traded up 0.39% during mid-day trading on Thursday, hitting $28.09. Genomic Health has a 52 week low of $19.00 and a 52 week high of $32.03. The company has a market cap of $840.1 million and a P/E ratio of 98.52.

The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.02 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.02) EPS by $0.04. The company’s quarterly revenue was up 17.4% on a year-over-year basis. On average, analysts predict that Genomic Health will post $0.02 earnings per share next quarter.

A number of other analysts have also recently weighed in on GHDX. Analysts at GARP Research downgraded shares of Genomic Health from a “buy” rating to a “neutral” rating in a research note to investors on Friday, February 17th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note to investors on Friday, February 10th. They now have a $28.00 price target on the stock. Finally, analysts at McNicoll Lewis & Vlak downgraded shares of Genomic Health to a “hold” rating in a research note to investors on Wednesday, February 8th.

Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services , which analyzes the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

About the author